Key result
Refractory heart failure despite optimized drug therapy is linked to a ~19% mortality rate.
Why the study?
To assess the severity of refractory heart failure.
Cross-Sectional (n=31)
No
Refractory heart failure is a major event in chronic heart failure evolution, with high mortality correlated with clinical, biological, and echocardiographic markers.
Answers are grounded in this paper and cite their sources.
Refractory HF carries high mortality and readmission risk despite optimized therapy; hypothesis-generating for predictors and interventions in chronic HF.
Objective: To assess the severity of refractory heart failure (RCI). Patients and method: This is a retrospective and cross-sectional study carried out in the cardiology department of Loandjili General Hospital in Pointe-Noire, Congo-Brazzaville between February 2022 and July 2022. We included records of patients in chronic heart failure (CHF) and RCI whose age ≥ 18 years who received optimized drug therapy. Study variables are biological, therapeutic, echocardiographic, prognosis, demographic, and clinical. P˂ 5% and the relative risk between 0-1 were significant. Results: 67 inpatient files were identified. 31 CCI files of which 20 RCMs were included. The prevalence of ICR was 29.8%. There were 18 men (58%) and 13 women (42%); sex ratio of 1.3. The mean age was 58.3± 15.3 years (range: 28-85) and correlated with sex (p˂5%). All patients (100%) had NYHA III/IV exertional dyspnea, and intense physical asthenia. Mean systolic blood pressure was 121.58±35.47 mm Hg (range: 60-250), correlated with exertional dyspnoea (P˂5%). There were comorbidities, a mean natremia of 138.94±11.62 mEq/l (range: 121-133), a mean serum creatinine of 14.08±5.63 mg/l (range: 6.65-34.8), a mean s BNP of 4040.9 ± 2957.2 pg/ml (ranges: 72.5-10423), a mean left ventricle ejection fraction of 30.95±11.65% (range: 9.63-55.9). The mean left ventricle telediastolic diameter was 63.7±7.8 mm (range: 40.7-75) correlated with exertional dyspnoea (p˂5%). Non-drug treatment was not protective against lethality (RR:1,1). The average hospital readmissions was 2.16±1 (range: 1-4) and the average length of hospital stay was 9±3.7 days (range: 4-20). Six patients (19.3%) with ICR had died. Mortality was correlated with certain clinical, biological and echocardiographic aspects (P˂5%). The mean peak of VO 2 was 22.41±5.2 ml/min/kg (range: 12-33.85), and that of the ELAN HF score was 4.51±1.48 (range: 2-8). Conclusion: The occurrence of RCM is a major eventin the evolution of CCI. Clinical, haemodic, biological, hospital readmission and different scoresare essential markers of prognostic evaluation. The deficit of the technical platform is amajor han dicap.
No takes yet. Share an insight, caveat, or question.
Bani Aloïse Macaire (2023) conducted a cross-sectional in Refractory heart failure (n=31). Refractory heart failure in patients receiving optimized drug therapy was associated with a 19.3% mortality rate and an average of 2.16 hospital readmissions.
Synapse has enriched 10 related papers. Consider them for comparative context: